Key Takeaways
- • Private equity completed 102 healthcare transactions in September 2025, comprising 14 buyouts, 62 add-on acquisitions, and 26 growth/expansion investments, demonstrating sustained PE momentum in the sector despite broader market conditions.
- • Clinical research consolidation emerged as a major PE focus in September, with at least five deals in the space, as firms pursue fragmented markets and exploit operational efficiencies such as accelerating drug-to-market timelines and reducing development costs.
- • Rovia Clinical Research, a Gauge Capital platform company, executed a significant roll-up strategy in September by acquiring Study Metrix and Coastal Research Institute, building on prior consolidation of ECIR, UACR, and IMIC Clinical Research Center.
- • Dental practice acquisitions continued to dominate PE healthcare activity in September, maintaining leadership among deal types and reflecting sustained interest in fragmented provider networks.
- • QHP Capital and undisclosed PE firms deployed growth capital into clinical trial operators including Vector Clinical Trials (formerly Las Vegas Medical Research) and Alta Thera Pharmaceuticals, signaling confidence in high-margin clinical services expansion.
Summary
Private equity healthcare dealmaking remained robust in September 2025, with the Private Equity Stakeholder Project (PESP) tracking 102 total transactions across multiple subsectors. The transaction mix comprised 14 leveraged buyouts, 62 add-on acquisitions, and 26 growth or expansion investments, reflecting PE's continued appetite for healthcare exposure despite broader macroeconomic headwinds. The concentration of add-on acquisitions underscores the sector's fragmentation and PE's platform-building consolidation strategies.
Clinical research emerged as a focal point for PE acquisition activity in September, with at least five dedicated deals in contract research organizations, clinical trial facilities, and pharmaceutical development support services. The sector's appeal to PE investors stems from structural advantages: fragmented market composition enables roll-up strategies with meaningful synergy potential, while operational improvements such as expedited drug development timelines and cost reduction directly drive enterprise value. Rovia Clinical Research, a platform company backed by Gauge Capital, exemplified this consolidation trend by acquiring both Study Metrix and Coastal Research Institute during the month. Rovia's track record demonstrates the model's viability, having previously consolidated East Coast Institute for Research (ECIR), Universal Axon Clinical Research (UACR), and IMIC Clinical Research Center into a larger operating platform.
Beyond Rovia's roll-up activity, complementary growth capital deployments in clinical research included QHP Capital's growth investment in Vector Clinical Trials, a Las Vegas-based clinical research site formerly operating under the Las Vegas Medical Research banner. An undisclosed PE firm also provided growth capital to Alta Thera Pharmaceuticals, reflecting investor confidence in pharmaceutical services expansion opportunities. Dental practice acquisitions maintained their position as the leading category of PE healthcare deals in September, continuing a pattern established earlier in 2025 and highlighting PE's strategic focus on fragmented primary care and specialty provider networks as vehicles for consolidation and operational leverage.
Clinical research emerged as a focal point for PE acquisition activity in September, with at least five dedicated deals in contract research organizations, clinical trial facilities, and pharmaceutical development support services. The sector's appeal to PE investors stems from structural advantages: fragmented market composition enables roll-up strategies with meaningful synergy potential, while operational improvements such as expedited drug development timelines and cost reduction directly drive enterprise value. Rovia Clinical Research, a platform company backed by Gauge Capital, exemplified this consolidation trend by acquiring both Study Metrix and Coastal Research Institute during the month. Rovia's track record demonstrates the model's viability, having previously consolidated East Coast Institute for Research (ECIR), Universal Axon Clinical Research (UACR), and IMIC Clinical Research Center into a larger operating platform.
Beyond Rovia's roll-up activity, complementary growth capital deployments in clinical research included QHP Capital's growth investment in Vector Clinical Trials, a Las Vegas-based clinical research site formerly operating under the Las Vegas Medical Research banner. An undisclosed PE firm also provided growth capital to Alta Thera Pharmaceuticals, reflecting investor confidence in pharmaceutical services expansion opportunities. Dental practice acquisitions maintained their position as the leading category of PE healthcare deals in September, continuing a pattern established earlier in 2025 and highlighting PE's strategic focus on fragmented primary care and specialty provider networks as vehicles for consolidation and operational leverage.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.